Matrix metalloproteinase inhibition after myocardial infarction: A new approach to prevent heart failure?

Circulation Research

Volumn 89, Issue 3, 2001, Pages 201-210

  Creemers, Esther E J M ^a   Cleutjens, Jack P M ^a   Smits, Jos F M ^a   Daemen, Mat J A P ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Matrix metalloproteinase inhibition; Myocardial infarction; Therapy

Indexed keywords

GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; TETRACYCLINE; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE PLASMINOGEN ACTIVATOR; TRANSFORMING GROWTH FACTOR BETA1; UROKINASE;

ANIMAL MODEL; CARDIOVASCULAR DISEASE; ENZYME INHIBITION; ENZYME REGULATION; EXTRACELLULAR MATRIX; HEART FAILURE; HEART INFARCTION; HEART MUSCLE; MOUSE; NONHUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; REVIEW;

EID: 0035800880     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/hh1501.094396     Document Type: Review

References (88)

1. Cellular mechanisms of myocardial expansion
2. Ventricular remodeling after myocardial infarction: Experimental observations and clinical implications
3. Impact of increased infarct transmurality on remodeling and function during healing after anterior myocardial infarction in the dog
4. Role of collagen in acute myocardial infarct expansion
5. Disruption of the myocardial extracellular matrix leads to cardiac dysfunction
6. Localization of matrix metalloproteinase 9 (92 kDa gelatinase/type IV collagenase=gelatinase B) in osteoclasts: Implications for bone resorption
7. Matrix metalloproteinase-2 is an interstitial collagenase: Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments
8. Matrix metalloproteinases in skin
9. Activation of human monocytes through CD40 induces matrix metalloproteinases
10. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes
11. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure
12. CD40 engagement modulates the production of matrix metalloproteinases by gingival fibroblasts
13. Cytokine regulation of metalloproteinase gene expression
14. MMP-9 from TNFα-stimulated keratinocytes binds to cell membranes and type I collagen: A cause for extended matrix degradation in inflammation
15. Activation mechanisms of matrix metalloproteinases
16. Regulation of matrix metalloproteinase activity
17. A matrix metalloproteinase expressed on the surface of invasive tumour cells
18. Cell surface binding activation of gelatinase A induced by expression of membrane-type-1-matrix metalloproteinase (MT1-MMP)
19. The role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction
20. Furin-dependent intracellular activation of the human stromelysin-3 zymogen
21. Activation of a recombinant membrane type 1-matrix metalloproteinase (MT-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2
22. Preparation and characterization of recombinant tissue inhibitor of metalloproteinase 4 (TIMP-4)
23. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4
24. Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2)
25. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells: A possible new growth factor in serum
26. Breast cancer, tumor neovasculature and the effect of tissue inhibitor of metalloproteinases-1 (TIMP-1) on angiogenesis
27. Divergent effects of tissue inhibitor of metalloproteinase-1, -2 or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis
28. Remodeling MMPIs
29. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials
30. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of metalloproteinases
31. Ro 32-3555, and orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo
32. Metalloproteinase inhibitors and wound healing: A novel enhancer of wound strength
33. Low molecular weight inhibitors in corneal ulceration
34. Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury
35. Oral matrix metalloproteinase inhibition and arterial remodeling after balloon dilation
36. The distribution of collagenase in normal rat tissues
37. Regulation of collagen degradation in the rat myocardium after infarction
38. Matrix metalloproteinase expression and activity in adult ventricular myocytes: Influence of basement membrane adhesion
39. Direct extraction and estimation of collagenase(s) activity by zymography in microquantities of rat myocardium and uterus
40. Post-transcriptional regulation of extracellular regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy
41. Early activation of metalloproteinases after experimental myocardial infarction occurs in infarct and non-infarct zones
42. Delayed reperfusion alters matrix metalloproteinase activity and fibronectin mRNA expression in the infarct zone of the ligated rat heart
43. Connective tissue changes in early ischemia of porcine myocardium: An ultrastructural study
44. Increased amounts of collagenase and gelatinase in porcine myocardium following ischemia and reperfusion
45. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice
46. Inhibition of matrix metalloproteinase (MMP) activity in mice reduces LV remodeling and depresses cardiac function after myocardial infarction
47. In vivo collagen turnover following experimental balloon angioplasty injury and the role of matrix metalloproteinases
48. Processing of tumour necrosis factor-α precursor by metalloproteinases
49. Generation of biologically active IL-1/3 by matrix metalloproteinases: A novel caspase-1-independent pathway of IL-1/β processing
50. Collagen synthesis by human fibroblasts: Regulation by transforming growth factor-β in the presence of other inflammatory mediators
51. Inhibition of plasminogen activators or matrix metalloproteinases prevent cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure
52. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction
53. Differential gene expression of extracellular matrix components in dilated cardiomyopathy
54. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure
55. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy
56. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart
57. Myocardial matrix metalloproteinase activity and abundance with congestive heart failure
58. Matrix metalloproteinase inhibition during the development of congestive heart failure: Effects on left ventricular dimensions and function
59. Polymorphism in matrix metalloproteinase gene promotors: Implication in regulation of gene expression and susceptibility of various diseases
60. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis
61. Time dependent alterations of serum matrix metalloproteinase-1 and metalloproteinase-1 tissue inhibitor after successful reperfusion of myocardial infarction
62. Peripheral blood levels of matrix metalloproteinase-2 and -9 are elevated in patients with acute coronary syndromes
63. Matrix metalloproteinase activity expression in infarcted, noninfarcted and dilated cardiomyopathic human hearts
64. Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase-type 1 (TIMP-1) on left ventricular geometry and function in mice
65. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation
66. Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction
67. 1 by plasmin
68. Congenital and acquired deficiencies of components of the fibrinolytic system and their relation to bleeding and thrombosis
69. Inactivation of tissue inhibitor of metalloproteinases by neutrophil elastase and other serine proteinases
70. Neutrophil-derived serine proteases enhance membrane type-1 matrix metalloproteinase-dependent tumor cell invasion
71. Cardioprotection by a novel recombinant serine protease inhibitor in myocardial ischemia and reperfusion injury
72. Novel recombinant serpin, LEX-032, attenuates myocardial reperfusion injury in cats
73. Validation of a mouse conductance system to determine LV volume: Comparison to echocardiography and crystals
74. Preclinical and clinical studies of MMP inhibitors in cancer
75. Distinct populations of stromal cells express collagenase-3 (MMP-13) and collagenase-1 (MMP-1) in chronic ulcers but not in normally healing wounds
76. Tumor targeting with a selective gelatinase inhibitor
77. Matrix metalloproteinase inhibitor prevents acute lung injury after cardiopulmonary bypass
78. Synthetic inhibitors of matrix metalloproteinases
79. Identification of MMP-18, a putative novel matrix metalloproteinase
80. Identification and characterization of the fifth membrane-type matrix metalloproteinase MT5-MMP
81. Identification and characterization of a novel human matrix metallopreteinase with unique structural characteristics, chromosomal location, and tissue distribution
82. Tumor necrosis factor bifunctionally regulates matrix metalloproteinases and tissue inhibitors of metallopreteinases (TIMP) production by human fibroblasts
83. Expression of tissue inhibitor of metalloproteinases-3 in human atheroma and regulation in lesion-associated cells
84. Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors of metalloproteinases-1, -2 and -3 in rabbit aortic smooth muscle cells
85. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: Role of flt-1
86. Differential regulation of monocyte matrix metalloproteinase and TIMP-1 production by TNF-α, granulocyte-macrophage CSF, and IL-1β through prostaglandin-dependent and -independent mechanisms
87. Cell-specific induction of distinct oncogenes of the jun family is responsible for differential regulation of collagenase gene expression by transforming growth factor β in fibroblasts and keratinocytes
88. Tissue inhibitor of metalloproteinases: Structure, regulation and biological functions